1. Wearing Off in Parkinson Disease: The Value of New Generation COMT Inhibition

3. Program Overview

4. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

5. Clinical Case of 46-Year-Old Victor: Initial Presentation

6. Victor: Presenting Symptoms

7. Victor: On Examination

8. Clinical Case: Clinician Perspective on Diagnosis (I)

9. Clinical Case: Clinician Perspective on Diagnosis (II)

10. Early Non-Motor Signs of PD

11. Rationale for Medical Treatment of Victor

12. Current First-Line Treatments for PD: Benefits and Limitations

13. Clinician Treatment Recommendation for Victor

14. Case Continuation: Initial Treatment Approach

15. Case Continuation: Treatment Follow-up

16. Clinician Treatment Recommendation for Victor

17. Victor: Next Treatment Step

18. Victor: 3 Years Later

19. Characteristics and Mechanisms of Levodopa-Related Motor Fluctuations in PD

20. Early Morning Off Is Prevalent in all PD Stages: EUROPAR Study

21. EUROPAR Study: NMS during EMO

22. Approaches to Address Motor Fluctuations

23. Approaches to Address Motor Fluctuations: Add-on Treatments

24. Mechanism of COMT Inhibition

25. COMT Inhibitors: Entacapone, Tolcapone, and Opicapone

26. Entacapone and Tolcapone: Reduction in Off- Time

27. BIPARK I: Change in Absolute "Off" Time in Hours

28. Most Common AEs With Opicapone and Entacapone

29. One-Year Open-label Extension of BIPARK: Results for "Off" Time

30. BIPARK-I and -II: Tolerability

31. Retrospective Analysis of the Opicapone Treatment in a PD Clinic in Germany 

32. Retrospective Analysis of Opicapone Treatment in Germany: Tolerability

33. Practical Experience With Switching From Entacapone to Opicapone

34. Combined COMT Inhibition and Intrajejunal Levodopa Infusion: Single-Center Experience

35. Concluding Remarks

36. Concluding Remarks (cont)

37. Abbreviations

38. Abbreviations (cont)